Reason for request
Reassessment of actual benefit and improvement in actual benefit under article R-163-21 of the Social Security Code.
Clinical Benefit
| Moderate |
The actual benefit is moderate. |
Clinical Added Value
| minor |
The Transparency Committee is of the opinion that the REMODULIN range of proprietary drugs provides a minor improvement in actual benefit (IAB IV) in the treatment of idiopathic pulmonary arterial hypertension for patients in functional class III. |
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
sJ8e5ktRZwjD7915
Listen
